News|Articles|November 18, 2026

Elticertinib Receives FDA Fast Track Designation in EGFR Exon 20–Mutated NSCLC

Author(s)Ryan Kret
Fact checked by: Chris Ryan
Listen
0:00 / 0:00

Key Takeaways

  • Fast track targets a high unmet-need post–platinum and post-amivantamab EGFR exon 20 insertion NSCLC population, enabling closer FDA interactions to potentially accelerate development timelines.
  • Irreversible EGFR/HER2 exon 20 inhibition leverages mutant-specific conformational dynamics to improve discrimination versus wild-type EGFR, with preclinical assays and xenografts demonstrating selective activity and regression.
SHOW MORE

The FDA has granted fast track designation to elticertinib (PFL-721; STX-721) for the treatment of adult patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations who have experienced disease progression after both platinum-based chemotherapy and amivantamab-vmjw (Rybrevant).1

Nonclinical data and early efficacy findings from an ongoing phase 1/2 study (NCT06043817) of the investigational agent supported the designation.

Dose-escalation data presented at the 2026 ASCO Annual Meeting showed that elticertinib given at doses of 360 mg or higher once daily (n = 28) produced an overall response rate of 54% (95% CI, 33.9%-72.5%) and a disease control rate of 79% (95% CI, 59.0%-97.7%).2

“This designation underscores the urgent need for new treatment options for patients with EGFR exon 20 insertion–mutated NSCLC, who still face limited efficacy and significant tolerability challenges with currently available therapies. It will allow us to engage more closely with the FDA to accelerate elticertinib development and bring this targeted therapy to patients faster,” Marie-Andrée Gamache, chief executive officer of Pierre Fabre Pharma, stated in a news release.1

What is the mechanism of action of elticertinib?

Elticertinib is an orally administered, irreversible TKI designed to target exon 20 insertion mutations in EGFR and HER2. The agent was engineered to discriminate between mutant receptors and wild-type EGFR, which plays a key role in the maintenance of normal epithelial tissue.3

In preclinical structural studies, the compound appeared to take advantage of shifting protein conformations linked to exon 20 insertion mutations. Biochemical and cell-based assays showed selective inhibition of the mutant receptors, and xenograft models demonstrated tumor regression.

How is the phase 1/2 trial designed?

The open-label, first-in-human study plans to enroll approximately 345 adults with stage IIIB/C or IV NSCLC for whom curative-intent surgery or chemoradiation is not an option.4 A qualified local laboratory must verify the presence of an EGFR or HER2 exon 20 insertion mutation.

Eligible patients must have measurable disease per RECIST 1.1 criteria, documented disease progression, and an ECOG performance status of 0 or 1. Patients in the dose-escalation portion must have exhausted, or be ineligible for, all approved therapies. Those enrolling in parts 2 and 3 must have received 1 or 2 prior lines of approved treatment, including platinum-based chemotherapy unless it was contraindicated.

Key exclusion criteria include symptomatic metastases to the brain or spine, the EGFR p.H773_V774insH variant, and activating EGFR kinase-domain mutations that co-occur with T790M and/or C797S resistance mutations.

The trial consists of monotherapy dose escalation, selection of the recommended phase 2 dose, and dose expansion, as well as cohorts evaluating elticertinib plus platinum-based chemotherapy.

Primary end points include dose-limiting toxicities (DLTs) during the first 28 days of treatment, pharmacokinetic exposure, and investigator-assessed confirmed objective response.

What safety findings were reported?

Among the 45 patients included in the dose-escalation analysis, 96% experienced adverse effects (AEs), and 87% had gastrointestinal AEs.2 Grade 3 or higher AEs included diarrhea (22%), hypokalemia (9%), and elevated blood creatinine levels (7%). A single grade 3 rash event was reported.

The maximum tolerated dose was 480 mg once daily. Six DLTs occurred among 39 evaluable patients and consisted of diarrhea, fatigue, and hypokalemia.

References

  1. Laboratoires Pierre Fabre: FDA fast track designation for elticertinib in NSCLC. News release. Pierre Fabre Laboratories. November 17, 2026. Accessed November 18, 2026. https://www.prnewswire.com/news-releases/laboratoires-pierre-fabre--fda-fast-track-designation-for-elticertinib-in-nsclc-302941043.html
  2. Gazzah A, Lin CC, Ruiter G, et al. First-in-human dose-escalation study of the selective EGFR/HER2 exon 20 inhibitor PFL-721 in patients with locally advanced or metastatic NSCLC. J Clin Oncol. 2026;44(suppl 16):8619. doi:10.1200/JCO.2026.44.16_suppl.8619
  3. Pagliarini RA, Henderson JA, Milgram BC, et al. STX-721, a covalent EGFR/HER2 exon 20 inhibitor, utilizes exon 20-mutant dynamic protein states and achieves unique mutant selectivity across human cancer models. Clin Cancer Res. 2025;31(14):3002-3018. doi:10.1158/1078-0432.CCR-24-3833
  4. First-in-human study of STX-721/PFL-721 in participants with locally advanced or metastatic non-small cell lung cancer harboring EGFR or HER2 exon 20 insertion mutations. ClinicalTrials.gov. Updated October 30, 2026. Accessed November 18, 2026. https://clinicaltrials.gov/study/NCT06043817


Related to this article